FAM53A Affects Breast Cancer Cell Proliferation, Migration, and Invasion in a p53-Dependent Manner.
breast cancer
cell migration
epithelial-mesenchymal transition (EMT)
extracellular-signal-regulated kinase (ERK)
invasion
metastasis
p53
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2019
2019
Historique:
received:
10
08
2019
accepted:
29
10
2019
entrez:
5
12
2019
pubmed:
5
12
2019
medline:
5
12
2019
Statut:
epublish
Résumé
Family with sequence similarity 53-member A (FAM53A) is an uncharacterized protein with a suspected but unclear role in tumorigenesis. In this study, we examined its role in breast cancer. Immunohistochemical staining of specimens from 199 cases of breast cancer demonstrated that FAM53A levels were negatively correlated with p53 status. In the p53 wild-type breast cancer cell line MCF-7, FAM53A overexpression inhibited cell migration, invasion, and proliferation, downregulated the expression of Snail, cyclin D1, RhoA, RhoC, and MMP9, and decreased mitogen-activated protein kinase kinase (MEK) and extracellular-signal regulated kinase (ERK) phosphorylation. Concurrently, it upregulated E-cadherin and p21 expression levels. Interestingly, opposite trends were observed in the p53-null breast cancer cell line MDA-MB-231. The MEK inhibitor PD98059 reduced the biological effects of FAM53A knockdown in MCF-7 cells and FAM53A overexpression in MDA-MB-231 cells, suggesting that FAM53A affects breast cancer through the MEK-ERK pathway. Silencing
Identifiants
pubmed: 31799197
doi: 10.3389/fonc.2019.01244
pmc: PMC6874147
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1244Informations de copyright
Copyright © 2019 Zhang, Sun, Hao, Diao, Wang, Li, Cao and Mi.
Références
Mol Cytogenet. 2015 Feb 28;8:15
pubmed: 25774220
Int J Oncol. 2006 Aug;29(2):341-7
pubmed: 16820875
Oncotarget. 2017 Mar 14;8(11):18381-18398
pubmed: 28179588
Hum Mutat. 2006 Jan;27(1):14-20
pubmed: 16278824
Eur J Cancer. 2018 Nov;103:41-51
pubmed: 30205280
Future Oncol. 2010 May;6(5):655-63
pubmed: 20465381
Oncol Lett. 2017 Apr;13(4):2216-2220
pubmed: 28454383
Int J Mol Med. 2005 Oct;16(4):735-40
pubmed: 16142413
Biomed Rep. 2014 May;2(3):321-325
pubmed: 24748967
Oncogene. 2007 May 14;26(22):3291-310
pubmed: 17496923
Sci Rep. 2016 Jul 04;6:29173
pubmed: 27373372
Leukemia. 2002 Apr;16(4):486-507
pubmed: 11960326
J Biol Chem. 2012 Sep 21;287(39):32346-53
pubmed: 22865885
Clin Cancer Res. 2006 Feb 15;12(4):1157-67
pubmed: 16489069
Dev Dyn. 2002 May;224(1):116-23
pubmed: 11984880
Drug Discov Today. 2011 Jun;16(11-12):485-94
pubmed: 21511051
Development. 2014 Sep;141(18):3529-39
pubmed: 25183871
Oncol Lett. 2018 Feb;15(2):1549-1558
pubmed: 29434849
Oncol Lett. 2017 Sep;14(3):3587-3593
pubmed: 28927116
PLoS One. 2017 May 2;12(5):e0176778
pubmed: 28463969
Oncogene. 2007 May 14;26(22):3279-90
pubmed: 17496922
Nature. 1992 Jul 30;358(6385):417-21
pubmed: 1322500
Proc Natl Acad Sci U S A. 2001 Jul 3;98(14):7783-8
pubmed: 11427728
Mol Oncol. 2017 Jul;11(7):805-823
pubmed: 28599100
Mol Cancer. 2009 Oct 01;8:81
pubmed: 19796390
Cell Cycle. 2006 Apr;5(8):824-8
pubmed: 16627995
EMBO J. 1992 Aug;11(8):2903-8
pubmed: 1322292
Development. 2006 May;133(10):1881-90
pubmed: 16611694
Tumour Biol. 2014 Apr;35(4):2989-95
pubmed: 24241960
Science. 1992 Oct 16;258(5081):478-80
pubmed: 1411546
Science. 1990 Jul 6;249(4964):64-7
pubmed: 2164259
Endocr Relat Cancer. 2018 Nov 1;:null
pubmed: 30407916
J Clin Invest. 1997 Apr 1;99(7):1478-83
pubmed: 9119990
PLoS One. 2015 Apr 17;10(4):e0122651
pubmed: 25884493